A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer

International Journal of Clinical Oncology, 05/07/2012

Shitara K et al. – Although the retrospective nature of this study and the small number of patients is a major limitation, S–1 plus cisplatin (SP) and capecitabine plus cisplatin (XP) were associated with similar efficacy and safety in patients with advanced gastric cancer (AGC).


  • The authors retrospectively compared the efficacy and safety of SP and XP in first-line treatment for patients with AGC.


  • From August 2006 to November 2008, 26 AGC patients received XP in the context of 2 global trials (AVAGAST and ToGA), and 50 patients received SP during the same period.
  • The objective response rate was 43.2 % in the SP group and 50 % in the XP group, with no significant difference (p=0.62).
  • There were also no significant differences in progression-free survival (median 5.8 vs. 5.2 months; p=0.91) and overall survival (median 13.8 vs. 13.5months; p=0.97) between the SP and XP groups.
  • The frequencies of hematological toxicities of grade 3 or more and non-hematological toxicities were not significantly different between the 2 groups.
  • Although grade 1 or 2 hand–foot syndrome was more common in the XP group, no patients experienced grade 3 or more.

Print Article Summary Cat 2 CME Report